Peptides for Weight Loss: What the Evidence Actually Shows

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Some medications discussed are FDA-approved prescription drugs requiring physician supervision; others are investigational or not approved for weight-related indications. Do not start, stop, or change any treatment without consulting a licensed healthcare provider.

“Peptides for weight loss” is one of the most searched phrases in the peptide space — and one of the most aggressively marketed. The honest answer to what peptides can actually do for weight and body composition is considerably more nuanced than most online sources suggest: a few have powerful, well-documented effects; a few have interesting but limited evidence; and many have no meaningful weight-related evidence at all despite being marketed as fat-burning or metabolic compounds.

This guide maps the full landscape, organized by evidence strength.

Obesity as a Neurobiological Disease: Why This Changes the Framework

Understanding why certain peptides work for weight management — and why willpower-based approaches have a documented 95%+ long-term failure rate — requires understanding what obesity actually is biologically.

The body weight set point is the weight range the hypothalamus actively defends through hormonal and neurological feedback. It is not a number you consciously choose; it is a physiological target the brain treats as correct, much as it treats normal blood pressure or body temperature as a target. In obesity, this set point is established at a higher weight through interactions of genetics, early development, stress hormones, gut microbiome, sleep disruption, and environmental food cues.

When weight drops below the defended set point — whether through caloric restriction, exercise, or drugs — the hypothalamus responds with:

Increased ghrelin (hunger intensification — ghrelin is a 28-amino-acid peptide acylated at Ser3 by GOAT (ghrelin O-acyltransferase) in gastric oxyntic mucosa X/A-like cells; it is the only known peripherally-produced orexigenic hormone. As gastric volume falls during caloric restriction, tonic mechanical stretch-receptor inhibition of ghrelin-secreting cells is relieved → ghrelin secretion rises into portal and systemic circulation. Ghrelin binds GHSR-1a (growth hormone secretagogue receptor 1a), a constitutively active Gq/11-coupled GPCR with highest expression on arcuate nucleus NPY/AgRP neurons and on pituitary somatotrophs. GHSR-1a/Gαq → PLCβ → IP₃ (inositol trisphosphate) + DAG → IP₃ binds IP₃R on ER membrane → ER Ca²⁺ release → intracellular Ca²⁺ elevation activates CaMKKβ (Ca²⁺/calmodulin-dependent protein kinase kinase β) → CaMKKβ phosphorylates AMPK at Thr172 directly in NPY/AgRP neurons → activated AMPK inactivates ACC → malonyl-CoA falls → CPT1 disinhibition → enhanced fatty acid β-oxidation in the NPY/AgRP neuron → sustained energetic substrate for sustained orexigenic firing. The resulting NPY release from axon terminals acts on NPY1R (Y1) and Y5R on PVN neurons → Gαi/o → reduced cAMP → suppressed satiety output from the paraventricular nucleus; simultaneously, AgRP co-released from the same terminals acts as an inverse agonist at MC4R on PVN neurons — not merely blocking α-MSH binding but actively suppressing MC4R’s constitutive Gαs/cAMP satiety tone below its unliganded baseline. This ghrelin-driven NPY/AgRP activation is mechanistically opposite to leptin’s ARC action: leptin suppresses NPY/AgRP and activates POMC/α-MSH/MC4R; ghrelin activates NPY/AgRP and suppresses MC4R constitutive signaling through AgRP inverse agonism — during caloric restriction, rising ghrelin amplifies orexigenic drive simultaneously with falling leptin removing satiety signaling, creating a converging bidirectional hunger intensification that cannot be overcome by motivation alone)
Reduced leptin (the satiety/fullness signal from fat cells — the mechanism by which falling leptin perpetuates hunger is specific and explains why caloric restriction becomes progressively harder over time. Leptin is secreted by adipocytes in direct proportion to their triglyceride content: fuller fat cells → more leptin secreted into circulation. In the hypothalamic arcuate nucleus (ARC), leptin binds leptin receptor isoform b (LepRb) on two opposing neuronal populations. On POMC neurons: LepRb → JAK2 (Janus kinase 2) autophosphorylation → JAK2 phosphorylates STAT3 at Tyr705 → pSTAT3 homodimerizes → nuclear translocation → STAT response element (GAS element) in the POMC gene promoter → increased POMC (pro-opiomelanocortin) transcription → POMC protein is cleaved by PC1/3 (prohormone convertase 1/3) → α-MSH (α-melanocyte-stimulating hormone) released as a neuropeptide → α-MSH binds MC4R (melanocortin-4 receptor) on paraventricular nucleus (PVN) neurons → Gs/cAMP/PKA → anorexigenic output (reduced food intake, increased energy expenditure). On NPY/AgRP neurons: LepRb/JAK2/STAT3 signaling in these neurons is inhibitory — activated LepRb drives STAT3-mediated transcriptional suppression of NPY (neuropeptide Y) and AgRP (agouti-related peptide) expression, reducing the output of these orexigenic neurons. AgRP is an inverse agonist at MC4R — it does not merely block α-MSH but actively suppresses MC4R’s constitutive signaling, directly opposing POMC-derived satiety. When caloric restriction reduces fat mass → adipocyte triglyceride content falls → leptin secretion drops → less JAK2/STAT3 activation on both neuronal populations → POMC neurons have reduced α-MSH output (less satiety signaling) → NPY/AgRP neurons are disinhibited, secreting more hunger-driving peptides → AgRP actively suppresses the already-weakened MC4R satiety signal. This bidirectional collapse of the leptin/melanocortin axis — less anorexigenic α-MSH and more orexigenic AgRP simultaneously — is why the hunger rebound from caloric restriction is mechanistically robust and cannot be overcome by willpower; it is a hormonal state, not a motivational failure)
Reduced PYY and native GLP-1 — post-meal satiety signal attenuation during caloric restriction: PYY (Peptide YY) and native GLP-1 are co-secreted from L-cells — enteroendocrine cells concentrated in the distal ileum and colon, with the highest density in the rectosigmoid. L-cells detect luminal nutrients through apically expressed G protein-coupled receptors: GPR119 responds to monoacylglycerols and fatty acid ethanolamides generated by fat digestion; GPR40 (FFAR1) responds to long-chain free fatty acids; GPR120 (FFAR4) responds to omega-3 fatty acids; TGR5 responds to bile acids that reach the ileum in amounts proportional to fat content of the meal. These receptors couple to Gαs → adenylyl cyclase → intracellular cAMP → PKA activation → exocytosis of L-cell secretory granules releasing both PYY and GLP-1 into portal and systemic circulation. During caloric restriction, total nutrient delivery to the distal gut is reduced proportionally to food intake: less fat and protein reaching the ileum → less GPR119/GPR40/TGR5 stimulation per meal → lower cAMP per L-cell → attenuated PYY and native GLP-1 co-secretion. PYY₃₋₃₆ (the active form, cleaved from full-length PYY₁₋₃₆ by DPP-IV) binds NPY2R (Y2 receptor) on NPY/AgRP neuronal axon terminals in the hypothalamic arcuate nucleus — Y2R is a presynaptic Gi-coupled inhibitory autoreceptor: PYY₃₋₃₆/Y2R/Gαi → reduced cAMP → suppressed Ca²⁺-evoked NPY/AgRP vesicular release → reduced orexigenic output. When caloric restriction reduces L-cell GPR stimulation → less PYY₃₋₃₆ secreted → Y2R occupancy on AgRP terminals falls → NPY/AgRP neurons become relatively disinhibited → additional hunger-promoting drive is added on top of the falling leptin/JAK2/STAT3 signal described above. Pharmacological GLP-1R agonists (semaglutide, tirzepatide) replace the attenuated native GLP-1 signal at arcuate POMC neurons and vagal afferents — but PYY₃₋₃₆/Y2R presynaptic AgRP inhibition has no pharmacological substitute in current therapy. Its caloric-restriction-driven attenuation represents an uncompensated orexigenic input, explaining why patients on GLP-1 therapy may still experience inter-meal hunger despite pharmacological GLP-1R saturation, and why combining GLP-1R agonism with high-fiber, high-fat dietary patterns (which maximize ileal L-cell stimulation per calorie) provides additive satiety beyond what pharmacology alone achieves
Reduced resting energy expenditure (the body becomes more metabolically efficient to slow the loss). The dominant molecular mechanism is the leptin → TRH/TSH/T3 thyroid axis: as fat mass falls → adipocyte leptin secretion falls → in the hypothalamic paraventricular nucleus (PVN), LepRb on TRH (thyrotropin-releasing hormone) neurons loses JAK2/STAT3 activation → direct STAT3-driven TRH gene transcription falls → TRH secretion into the pituitary portal blood falls → pituitary TSH secretion falls → thyroid gland receives less TSH → less T4 synthesis → less conversion to active T3 (triiodothyronine) by type 2 deiodinase (DIO2) in peripheral tissues. T3 drives adaptive thermogenesis through two parallel effector arms. In brown adipose tissue: T3/TRβ1/RXRα heterodimer binds TREs (DR+4 hexamer half-sites) in the UCP1 promoter; when T3 falls, TRβ1/RXRα loses its activating ligand → recruits NCoR/SMRT/HDAC3 corepressor → histone deacetylation at the UCP1 promoter → UCP1 mRNA and protein fall → thermogenic uncoupling capacity per BAT cell decreases. In skeletal muscle: T3/TRβ1 drives transcription of sarcolipin (SLN) — a transmembrane peptide that associates with SERCA (sarcoplasmic reticulum Ca²⁺-ATPase) and physically uncouples its ATP hydrolysis from net Ca²⁺ pumping: each ATPase cycle hydrolyzes ATP but allows Ca²⁺ to “slip back” through the pump, converting the chemical energy to heat rather than electrochemical gradient. This SLN-mediated futile Ca²⁺ cycling accounts for approximately 25–30% of resting skeletal muscle heat output. When T3 falls during caloric restriction → less TRβ1-driven SLN transcription → more efficient SERCA Ca²⁺ pumping → lower metabolic rate per unit of lean mass → measured resting metabolic rate drops 10–15% below what lean mass loss alone would predict. This T3-mediated adaptive thermogenesis decline is mechanistically independent of the ghrelin, leptin, and PYY pathways described above — it operates as a fourth, parallel defense of the elevated body weight set point, explaining why caloric restriction alone becomes increasingly futile over time even with perfect compliance

This is documented rigorously: Sumithran et al. 2011 (NEJM) showed that hormonal changes induced by caloric restriction persist for 12 months after weight is fully regained (PMID:22029981) — meaning the body continues fighting to return to the higher weight long after any “diet” has ended.

The dopamine reward dysregulation adds a second dimension. In individuals with obesity, neuroimaging studies consistently show reduced dopamine receptor density (particularly D2 receptors) in the striatum — the brain’s reward hub. This creates a dynamic similar to substance tolerance: normal amounts of food produce less reward signal, which drives greater consumption to reach the same hedonic threshold. This is not weakness; it is a well-documented neurobiological state. The molecular mechanism of D2R downregulation in chronic overconsumption involves two parallel arms that compound each other. First, post-translational D2R degradation: chronic overconsumption of hyperpalatable foods → sustained high-amplitude dopamine release in the nucleus accumbens and dorsal striatum → elevated ambient synaptic dopamine chronically activates both postsynaptic D1Rs and D2Rs → sustained D2R/Gi activation recruits GRK2 (G protein-coupled receptor kinase 2) to the cytoplasmic C-terminal tail and third intracellular loop of D2R → GRK2 phosphorylates multiple Ser/Thr residues on D2R → β-arrestin 2 docks at the phosphorylated sites, sterically uncoupling D2R from Gi heterotrimer (terminating Gi-mediated signal) and simultaneously recruiting the clathrin heavy chain/AP2 adaptor complex → dynamin GTPase pinches off the D2R–β-arrestin–clathrin vesicle → early endosome formation → Rab7-mediated routing to late endosomes and lysosomes → lysosomal cathepsin-mediated D2R degradation, reducing surface D2R density per striatal neuron. Second, transcriptional D2R suppression via ΔFosB: repeated phasic dopamine release drives D1R/Gs/cAMP/PKA → CREB Ser133 → AP-1 transcription factors in striatal medium spiny neurons. Unlike acutely induced FosB (which degrades within hours), the truncated splice variant ΔFosB (FosB lacking the C-terminal degron domain responsible for ubiquitin-proteasome-mediated turnover) is uniquely stable — with repeated stimulation, ΔFosB accumulates in striatal nuclei over days to weeks because it is not cleared between stimulation cycles. Accumulated ΔFosB forms AP-1 heterodimers (ΔFosB/JunD) that bind AP-1 sequences in the DRD2 gene promoter and recruit HDAC1 (histone deacetylase 1) → local H3/H4 deacetylation → nucleosome compaction → transcriptional repression of DRD2 mRNA → reduced D2R protein synthesis. This ΔFosB-mediated D2R suppression becomes self-sustaining: fewer D2Rs per cell → weaker dopamine signal per meal → stronger dopaminergic response required to achieve reward threshold → greater food quantity needed → further phasic dopamine bursts → more ΔFosB accumulation. The resulting chronic hypodopaminergic tone in obese individuals mirrors the receptor downregulation seen in addiction, explaining both the compulsive quality of overconsumption and the reason appetite suppressants that do not address the reward-circuit substrate are insufficient to normalize eating behavior long-term.

Why GLP-1 agonists represent a genuine therapeutic advance: These drugs do not simply suppress appetite. They:

Pharmacologically override the hypothalamic set point defense by maintaining GLP-1R signaling even during caloric deficit — the signal that would normally decrease during weight loss is pharmacologically sustained
Attenuate mesolimbic dopamine responses to food cues — directly addressing the reward dysregulation that drives hedonic overconsumption. The mechanism operates at two anatomical sites simultaneously: (a) VTA dopamine neurons express GLP-1R (Gs-coupled) → cAMP/PKA activation → over weeks of sustained GLP-1R signaling, PKA-mediated phosphorylation upregulates the sensitivity of presynaptic D2 autoreceptors on dopamine terminals in the nucleus accumbens → stronger dopamine autoinhibition per action potential → less dopamine released per food-cue-evoked VTA burst → attenuated reward signal; (b) Nucleus accumbens (NAc) medium spiny neurons (D1-expressing direct pathway neurons) also express GLP-1R → Gs/cAMP/PKA → PKA phosphorylates GluA1 AMPA receptor subunit at Ser845 → phospho-GluA1 is trafficked away from synaptic sites (dephosphorylation promotes synaptic insertion; phosphorylation at Ser845 by PKA promotes endocytosis in some NAc neuron contexts, while in other circuits it promotes surface expression — the net effect in NAc GLP-1R/D1 neuron context appears to reduce AMPA receptor-mediated excitatory transmission) → reduced depolarization of NAc neurons in response to food-cue glutamate → less hedonic eating drive. Together these two mechanisms produce the “food noise” quieting that many patients describe as GLP-1 therapy’s most transformative subjective effect.
Improve leptin sensitivity over time, allowing smaller fat stores to produce adequate satiety signaling. The mechanism of GLP-1-mediated leptin sensitization centers on suppressing the hypothalamic inflammation cascade that is the primary driver of leptin resistance in obesity. Chronic overconsumption exposes hypothalamic microglia and neurons to elevated circulating saturated fatty acids (palmitate, stearate) → these act as TLR4 ligands on hypothalamic neurons and microglia → TLR4/MyD88/TRAF6 → IKKβ (IκB kinase β) activation → IKKβ phosphorylates IκBα at Ser32/36 → ubiquitylation and proteasomal degradation of IκBα → NF-κB (p65/p50) translocates to nucleus → NF-κB drives transcription of SOCS3 (suppressor of cytokine signaling 3). SOCS3 is the molecular mediator of central leptin resistance: SOCS3 binds phospho-Tyr985 on LepRb (via its SH2 domain), simultaneously blocking JAK2 access to the receptor and recruiting the E3 ubiquitin ligase elongin-BC/Cullin-5, which ubiquitylates LepRb → lysosomal degradation of the receptor-SOCS3 complex → reduced surface LepRb density → attenuated JAK2/STAT3/POMC signaling even when leptin circulates at physiologically appropriate concentrations. GLP-1R/Gs/cAMP → PKA phosphorylates IKKβ at Ser180 (an inhibitory site that prevents IKKβ from phosphorylating IκBα) → IκBα remains intact → NF-κB remains cytoplasmic → SOCS3 transcription falls → reduced SOCS3 protein → LepRb Tyr985 is accessible for JAK2 signaling → restored LepRb/JAK2/STAT3 → restored POMC → α-MSH → MC4R anorexigenic tone. This GLP-1 → cAMP → PKA → IKKβ inhibition → NF-κB suppression → SOCS3 reduction pathway is the molecular basis for the observed improvement in leptin sensitivity with sustained GLP-1 agonist treatment — it is not a direct effect on adipocytes or leptin production, but a restoration of signal transduction fidelity in hypothalamic neurons that have been chronically inflamed by the pre-treatment diet environment

This is why GLP-1 agonists produce 15–22% weight loss in clinical trials when 12-month behavioral interventions produce 3–5%. The pharmacology is addressing the neurobiological drivers of the disease, not simply telling people to eat less.

Implication for peptide therapy decisions: Compounds that do not address these neurobiological mechanisms — appetite suppression via GLP-1R/GIP-R, dopamine modulation, set-point resetting — are not comparable to GLP-1 agonists for obesity treatment, regardless of their fat-burning mechanisms at the cellular level. AOD-9604’s β3-AR lipolysis and tesamorelin’s IGF-1-driven visceral fat reduction are real mechanisms for real problems — but they are adjuncts, not alternatives, to the neurobiological approach that GLP-1 drugs provide.

Adipose Tissue Biology: Why Different Peptides Target Different Fat Compartments

Not all body fat is the same, and understanding the differences explains why different peptides have different applications:

Visceral vs. Subcutaneous Fat

Visceral adipose tissue (VAT): Surrounds abdominal organs (liver, pancreas, intestines). Metabolically active in a pathological sense — releases high levels of inflammatory cytokines (TNF-α, IL-6, resistin) and free fatty acids directly into the portal vein, contributing to hepatic insulin resistance, dyslipidemia, and cardiovascular risk. Has higher GH receptor density than subcutaneous fat, making it more responsive to IGF-1 signaling (which is why tesamorelin preferentially reduces visceral fat).

The mechanistic explanation for why VAT is more metabolically harmful than subcutaneous fat of equivalent mass involves three converging biological properties specific to the visceral depot:

Why VAT generates more inflammatory output than subcutaneous fat. As visceral adipocytes expand beyond their lipid storage capacity in obesity, two stress signals converge simultaneously. First, enlarging VAT mass outgrows its capillary supply → intracellular hypoxia → HIF-1α (hypoxia-inducible factor-1α) stabilization (normally targeted for von Hippel–Lindau E3 ubiquitin ligase degradation via hydroxylation by PHD2, but PHD2 requires O₂ as substrate and loses activity in hypoxic conditions) → HIF-1α/ARNT heterodimer binds HREs in the promoters of MCP-1 (CCL2) (macrophage chemoattractant) and PAI-1 → crown-like structures form as macrophages infiltrate around dying adipocytes → M1-polarized macrophage TLR4/NF-κB → TNF-α, IL-6, and additional MCP-1 secretion in a feedforward loop. Second, hypertrophied VAT adipocytes themselves express abundant TLR4, which detects the elevated circulating saturated fatty acids (palmitate, stearate) present in obesity as low-grade TLR4 ligands → TLR4/MyD88/IRAK4/TRAF6 → IKKβ → NF-κB → TNF-α, IL-6, IL-1β, and resistin transcription in the adipocyte itself. Visceral adipocytes have approximately 3× higher TLR4 surface expression than subcutaneous adipocytes, explaining the depot-specific inflammatory amplification. Resistin (encoded by RETN) acts as a paracrine signal to neighboring adipocytes and macrophages, engaging TLR4 and CAP1 on those cells → additional NF-κB activation → sustained cytokine loop independent of ongoing TLR4 lipid sensing.

Why portal FFA delivery from VAT specifically causes hepatic insulin resistance. VAT’s omental and mesenteric depots drain directly into the portal vein, delivering VAT-derived free fatty acids at concentrations 30–60% higher in portal blood than in the systemic circulation. Hepatocytes exposed to this concentrated portal FFA flux take up long-chain fatty acids via FATP2/FATP5 transporters → intracellular esterification of ceramide (via serine palmitoyltransferase → dihydrosphingosine → ceramide) and diacylglycerol (DAG) accumulation exceeds the hepatocyte’s β-oxidation capacity during caloric excess. DAG activates PKCε (protein kinase C epsilon) at the plasma membrane → PKCε phosphorylates the insulin receptor’s kinase domain at Thr1160 (a Ser/Thr phosphorylation that impairs the receptor’s tyrosine kinase activation loop) → reduced insulin receptor Tyr autophosphorylation per insulin binding → impaired IRS-1 Tyr612/Tyr632 phosphorylation → reduced PI3K/Akt/AS160 signaling in hepatocytes → impaired glycogen synthase activation and continued hepatic glucose output despite circulating insulin — hepatic insulin resistance. Ceramide provides a parallel mechanism: ceramide activates PP2A (protein phosphatase 2A) which dephosphorylates and inactivates Akt Ser473 in hepatocytes, blocking insulin-stimulated glucokinase induction and FOXO1 nuclear exclusion. Subcutaneous adipose tissue (SAT) drains into the systemic femoral-iliac venous system, bypassing the portal vein entirely — SAT-derived fatty acids are diluted across the full systemic circulation before reaching the liver, reaching concentrations roughly one-third those of portal blood. This anatomical routing difference is the molecular explanation for why the VAT:SAT ratio is a stronger predictor of metabolic disease than total fat mass: the same total adipose load produces far greater hepatic lipotoxic and inflammatory stimulus when proportionally more is visceral.

Subcutaneous adipose tissue (SAT): Located under the skin. Metabolically less harmful than VAT at equivalent amounts. The ratio of VAT:SAT is a meaningful predictor of metabolic risk independent of total weight. The reasons SAT is less harmful extend beyond the portal routing distinction described above — they involve two additional mechanisms specific to SAT’s cellular biology. First, adiponectin secretion: SAT produces substantially more adiponectin per cell than VAT. Adiponectin acts through AdipoR1 on skeletal muscle → AMPK Thr172 phosphorylation → ACC inhibition → CPT1 disinhibition → increased fatty acid β-oxidation; and through AdipoR2 on hepatocytes → PPARα activation → β-oxidation gene transcription + reduced PEPCK (gluconeogenesis) → improved hepatic insulin sensitivity directly complementing the portal FFA/PKCε pathway. The reason VAT secretes less adiponectin connects to its own inflammatory biology: VAT’s 3× higher TLR4 expression → sustained NF-κB/IKKβ activation → IKKβ phosphorylates and disrupts PGC-1α (the coactivator that bridges PPARγ/RXR heterodimers to CBP/p300 at the ADIPOQ adiponectin gene promoter PPRE) → adiponectin transcription falls in proportion to NF-κB-driven inflammatory output. SAT’s lower TLR4 density maintains PPARγ/PGC-1α/ADIPOQ transcriptional competence → higher adiponectin secretion per cell. The consequence is a bidirectional divergence: VAT worsens hepatic insulin sensitivity directly (portal FFA/DAG/PKCε → impaired insulin receptor Tyr kinase) AND suppresses the adiponectin that would improve it via AdipoR2/PPARα — two orthogonal mechanisms amplifying the same hepatic dysfunction. Second, preadipocyte hyperplasia: SAT expansion can proceed through both adipocyte hypertrophy and adipocyte hyperplasia (differentiating new preadipocytes into fat-storing cells), distributing lipid across a larger cell number. VAT’s preadipocyte pool is more limited, so VAT expansion is predominantly hypertrophic — individual omental and mesenteric adipocytes enlarge to sizes that exceed capillary oxygen diffusion capacity (~100 µm), retriggering the HIF-1α → MCP-1 → crown-like structure inflammatory cascade. SAT’s hyperplastic capacity generates smaller-average-diameter adipocytes that remain below the HIF-1α hypoxia threshold, limiting the inflammatory amplification per unit of lipid stored.

GLP-1 agonists reduce both compartments, with VAT reduction often proportional to or slightly greater than total weight loss — consistent with the metabolic improvements (insulin resistance, lipids, blood pressure) that exceed what weight loss alone would predict. The mechanisms responsible for this excess benefit involve GLP-1R actions that are direct, rapid, and weight-independent: (1) Hepatic GLP-1R/cAMP/PKA → FOXO1 phosphorylation: GLP-1R is expressed on hepatocytes, and GLP-1R/Gs/cAMP/PKA activation in hepatocytes phosphorylates FOXO1 (forkhead box O1) at Ser256 → 14-3-3 proteins dock at phospho-Ser256 → FOXO1 is sequestered in the cytoplasm, preventing nuclear translocation. Nuclear FOXO1 drives transcription of G6PC (glucose-6-phosphatase) and PCK1 (PEPCK, phosphoenolpyruvate carboxykinase 1) — the rate-determining enzymes of hepatic glucose output and gluconeogenesis. GLP-1R-driven FOXO1 cytoplasmic sequestration reduces G6PC and PCK1 expression → hepatic glucose production falls within hours of GLP-1R agonist initiation, independently of and preceding any significant reduction in body weight. This explains the early fasting glucose improvements observed in clinical trials before substantial weight loss has occurred. (2) Direct visceral adipocyte GLP-1R/PKA → IKKβ inhibition: VAT adipocytes express GLP-1R, and GLP-1R/Gs/cAMP → PKA phosphorylates IKKβ at Ser180 (an inhibitory phosphorylation site that prevents IKKβ from engaging and phosphorylating IκBα) — reducing NF-κB nuclear translocation and attenuating TNF-α, IL-6, and resistin transcription in VAT adipocytes before VAT mass has meaningfully decreased. This reduces portal FFA and VAT-derived cytokine delivery to the liver at a rate faster than fat mass loss would achieve, improving hepatic insulin sensitivity and triglyceride metabolism before caloric deficit drives structural VAT reduction. Together, these two direct GLP-1R mechanisms — hepatic FOXO1 cytoplasmic sequestration reducing glucose output and VAT NF-κB/IKKβ inhibition reducing portal cytokine delivery — explain why cardiometabolic risk markers (fasting glucose, HOMA-IR, triglycerides, blood pressure) improve during the early weeks of GLP-1 therapy when total weight loss is still minimal, and why the metabolic benefit profile is disproportionately large relative to the weight lost compared to other weight-reduction approaches that lack these direct extra-adipose receptor activities.

Brown Adipose Tissue (BAT) and Thermogenesis

Brown adipose tissue (BAT) is a thermogenic fat depot that burns calories as heat rather than producing ATP efficiently. It does this through UCP1 (uncoupling protein 1), which dissipates the mitochondrial proton gradient.

How UCP1 generates heat: In normal mitochondria, the electron transport chain (Complexes I–IV) pumps H⁺ ions from the matrix into the intermembrane space, building a steep proton gradient. This gradient drives H⁺ back through ATP synthase (Complex V), producing ATP. UCP1 provides an alternative H⁺ channel that bypasses ATP synthase entirely — H⁺ leaks back into the matrix through UCP1 without producing ATP. The energy of the proton gradient is released as heat rather than stored as chemical energy. This is “uncoupling” because substrate oxidation continues (electrons still flow through the chain, consuming oxygen and fatty acids) but is no longer coupled to ATP production. UCP1 is activated by free fatty acids released during lipolysis — creating a feed-forward loop: lipolysis → free fatty acids → activate UCP1 → burn those same fatty acids as heat.

BAT is activated by cold exposure and β3-adrenergic receptor stimulation — through a specific sympathetic-to-adipocyte cascade that operates in two temporally distinct phases. Acute phase (minutes-to-hours): Cold detected by TRPM8/TRPA1 ion channels on cutaneous sensory neurons → ascending signal to the preoptic area (POA) of the hypothalamus, the thermoregulatory setpoint integrator. POA cooling removes warm-sensitive neuron inhibitory tone on the dorsomedial hypothalamus (DMH) → increased DMH excitatory output to sympathetic preganglionic neurons in the intermediolateral cell column (IML) → thoracic sympathetic ganglia → postganglionic norepinephrine (NE) release onto brown adipocytes through the dense sympathetic innervation of BAT (the highest sympathetic terminal density of any adipose depot). NE binds β3-AR (Gs-coupled) → adenylyl cyclase → cAMP → PKA activation → PKA phosphorylates perilipin-5 (BAT-specific lipid droplet coat protein), releasing ATGL from its inhibitory interaction with CGI-58/ABHD5 → ATGL catalyzes the rate-limiting triglyceride hydrolysis → diglycerides and FFA; PKA simultaneously phosphorylates HSL at Ser660 → HSL translocates to lipid droplet surface → completes DG and MG hydrolysis → three free fatty acids per triglyceride molecule. These liberated FFAs serve a dual thermogenic role: (1) they are oxidized as electron transport chain fuel, generating the proton gradient that UCP1 then dissipates; and (2) they directly activate UCP1 by displacing inhibitory purine nucleotides (GDP/ADP) from UCP1’s matrix-facing nucleotide-binding site — FFA binding to an adjacent hydrophobic pocket allosterically reverses nucleotide inhibition and opens the proton channel → H⁺ re-enters the matrix without driving ATP synthase → electrochemical gradient energy released as heat. The FFA/UCP1 interaction creates a feed-forward loop: β3-AR → PKA → HSL/ATGL → FFA → UCP1 opening AND more ETC substrate → more proton gradient → more heat per fatty acid oxidized. Chronic phase (hours-to-days): Sustained β3-AR → PKA → CREB Ser133 phosphorylation → CREB drives PPARGC1A promoter → PGC-1α synthesis → PGC-1α co-activates PPARα, PPARγ, ERRα, and NRF1/NRF2 → full thermogenic and mitochondrial biogenesis gene program: more UCP1 protein per mitochondrion (UCP1 gene has a β3-AR/PKA/CREB-responsive upstream enhancer amplified by PGC-1α/PPARγ), more CIDEA (mitochondrial fusion), more TFAM (mtDNA replication) → total mitochondrial mass per cell rises. Repeated cold exposure therefore progressively increases BAT thermogenic capacity beyond the first session’s response — both by activating existing UCP1 acutely and by expanding mitochondrial mass and UCP1 abundance chronically. This two-phase mechanism also explains why BAT expands in winter acclimatization and why acute β3-AR agonism produces immediate caloric expenditure while sustained agonism upregulates thermogenic capacity over weeks.

AOD-9604’s β3-AR mechanism is specifically relevant here: β3-adrenergic receptors are highly expressed in both BAT and white adipose tissue. β3-AR activation in BAT increases UCP1 expression and thermogenesis — burning fat for heat. β3-AR activation in white adipose activates hormone-sensitive lipase to release stored fatty acids into circulation for oxidation. This is the mechanistic basis of AOD-9604’s lipolytic profile and why it doesn’t affect IGF-1 or glucose metabolism.

Beige adipocytes (brite cells): White fat can be induced to behave more like brown fat through a process called “browning” or “beiging,” driven by cold, β3-AR agonism, and specific hormones — most notably irisin. Irisin is a myokine (muscle-derived hormone): during exercise, skeletal muscle expresses FNDC5 → ADAM proteases cleave its extracellular domain → irisin is released into circulation → irisin acts on white adipose tissue → upregulates UCP1 expression → promotes beiging. The molecular pathway from irisin to UCP1 transcription is now well characterized: irisin binds integrin αVβ5 on the surface of white adipocytes and preadipocytes → integrin clustering activates focal adhesion kinase (FAK) and integrin-linked kinase (ILK) → signaling converges on AMPK and p38 MAPK, the latter phosphorylating ATF2 (activating transcription factor 2) → ATF2 activates transcription of PRDM16 — the master transcriptional switch that determines brown/beige vs. white adipocyte fate. PRDM16 then physically interacts with and co-activates PGC-1α (the mitochondrial biogenesis master regulator); the PRDM16/PGC-1α complex drives expression of UCP1, CIDEA, PPAR-γ, and the full thermogenic gene program. The white adipocyte retains its lipid storage infrastructure but acquires thermogenic mitochondria capable of uncoupled respiration. This irisin/αVβ5/p38/ATF2/PRDM16/PGC-1α/UCP1 pathway is the molecular explanation for why resistance exercise — which generates substantial FNDC5/irisin — has metabolic benefits on fat tissue beyond its caloric cost (Boström et al., PMID:22297045; Zhang et al., PMID:30337094). This is the molecular link between exercise and enhanced thermogenesis in fat tissue — the same cells that store fat can be converted by exercise signals into partial thermogenic fat burners. GLP-1R activation has also been shown in preclinical studies to promote beige adipocyte activity, contributing to energy expenditure beyond caloric reduction — though the human evidence remains limited. The mechanistic basis is consistent with GLP-1R’s canonical Gs/cAMP signaling: GLP-1R/Gs → adenylyl cyclase → cAMP elevation in subcutaneous white adipocytes → PKA phosphorylates CREB at Ser133 → pCREB drives transcription of both PGC-1α and PRDM16 in white adipocytes and preadipocytes — precisely the co-activator pair that the irisin/p38/ATF2 beiging pathway described above converges on. The PGC-1α/PRDM16 complex then binds PPREs in the UCP1 −2.5 kb upstream enhancer, activating the thermogenic gene program. A second route may operate through central sympathetic outflow: GLP-1R activation in hypothalamic sympathetic premotor nuclei (VMH, LHA) → enhanced sympathetic nerve firing to white adipose tissue depots → norepinephrine released at adipocyte β3-AR → Gs/cAMP/PKA → ATGL/HSL lipolysis plus phospho-CREB → UCP1 induction. These parallel GLP-1/direct-adipocyte-cAMP and GLP-1/central-sympathetic/β3-AR beiging pathways would give GLP-1 agonists an energy-expenditure component that augments weight loss beyond caloric restriction alone — consistent with the observation that resting metabolic rate reductions during GLP-1 therapy are often smaller than predicted from caloric deficit alone.

The practical implication: visceral fat preferentially responds to GH axis interventions (tesamorelin); metabolically harmful VAT is also reduced by GLP-1 agonists; BAT thermogenesis is specifically the target of β3-AR compounds like AOD-9604; subcutaneous fat is reduced by GLP-1 agonists and caloric deficit but is less responsive to GH axis interventions.

The Lean Mass Loss Problem: Why Scale Weight Alone Is Misleading

Before reviewing specific compounds, one phenomenon warrants its own section: lean mass loss during weight loss therapy. This applies to GLP-1 drugs, GH secretagogues, and any calorie-restriction-based approach, but is most clinically important in the GLP-1 context given the large number of patients now using these medications.

The mechanism: Rapid caloric restriction signals the body to reduce energy expenditure through two routes — fat mobilization and muscle protein catabolism. Muscle protein breakdown provides amino acids that can be converted to glucose (gluconeogenesis) when dietary intake is low. This is evolutionarily appropriate in famine contexts; it becomes a clinical problem when pharmacologically-induced appetite suppression produces sustained caloric deficits faster than the body can adapt through fat mobilization alone.

Why muscle is the body’s first target for catabolism during caloric restriction is explained by two parallel molecular mechanisms that operate simultaneously:

Mechanism 1 — mTORC1 suppression reduces new protein synthesis: Caloric restriction → reduced insulin secretion and reduced dietary amino acid flux to muscle cells → mTORC1 (mechanistic target of rapamycin complex 1) loses its two primary activating inputs (insulin/IGF-1 via PI3K/Akt, and amino acids via Rag GTPase/Ragulator complex) → mTORC1 becomes insufficiently active to maintain baseline protein synthesis rates → reduced phosphorylation of S6K1 (ribosomal protein S6 kinase 1, which normally promotes ribosome biogenesis) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein, which normally releases eIF4E to permit cap-dependent mRNA translation) → both ribosome production and protein translation rates fall → the baseline rate of myofibrillar protein synthesis (which replaces degraded contractile proteins approximately every 7–10 days in healthy muscle) drops below the degradation rate.

Mechanism 2 — glucocorticoid/FOXO axis upregulates protein degradation: Caloric restriction elevates cortisol (HPA axis activates when energy availability falls) → cortisol/glucocorticoid receptor (GR) complex translocates to the nucleus in skeletal muscle → GR drives transcription of FOXO1 and FOXO3a (forkhead box transcription factors) → FOXO1/3a bind forkhead response elements (FREs) in promoters of two E3 ubiquitin ligases: MuRF1 (TRIM63), which targets myosin heavy chain, myosin binding protein C, troponin I, and titin for ubiquitylation; and MAFbx/atrogin-1 (FBXO32), which targets MyoD (the myogenic transcription factor maintaining muscle identity) and eIF3f (a translation initiation factor). MuRF1 and MAFbx tag their substrates with K48-linked polyubiquitin chains → the 26S proteasome recognizes the ubiquitin tag and unfolds/degrades the tagged contractile proteins.

The two mechanisms act in series: synthesis is reduced (mechanism 1) while degradation is maintained or increased (mechanism 2) → net negative protein balance → lean mass loss. The magnitude correlates with caloric deficit depth: at modest deficits (10–15% below maintenance), fat mobilization can supply most of the shortfall; at aggressive deficits driven by GLP-1-induced appetite suppression, the depth and duration of negative energy balance exceeds what fat mobilization alone can sustain, increasing the relative contribution from muscle catabolism. This is why the lean mass preservation protocol — resistance exercise (which activates mTOR independently of caloric state via mechanical/integrin signaling) and dietary protein at 1.2–1.6 g/kg/day (maintains amino acid inputs for mTOR activation and provides gluconeogenic substrate, reducing cortisol-driven muscle raiding) — directly counteracts both mechanisms simultaneously.

The magnitude: Phase 3 trial analyses of GLP-1 drugs estimate that 25–40% of total weight lost may be lean mass in patients not following muscle-preserving protocols. For a patient losing 20 kg total, this could mean 5–8 kg of lean mass lost alongside fat — a reduction that lowers resting metabolic rate and makes subsequent weight maintenance harder.

Why this matters for long-term outcomes: If a patient loses significant lean mass during GLP-1 therapy and then discontinues, weight regain is preferentially adipose — the regained weight is fat, not muscle. This creates a worse body composition than the starting point: same or higher weight with more fat and less muscle. The SURMOUNT-4 data showing near-complete weight regain after tirzepatide discontinuation is concerning partly for this reason.

The mitigation protocol: Resistance exercise 2–3 times per week (any compound movement — squats, deadlifts, rows, pressing — even at low intensity), dietary protein 1.2–1.6 g/kg/day (prioritizing complete protein sources at each meal), and monitoring body composition with DEXA rather than scale weight alone. Creatine monohydrate (3–5 g/day) has strong evidence for lean mass preservation during caloric restriction.

Tier 1: FDA-Approved — Strong Clinical Evidence

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide): How They Actually Work

These are not research peptides — they are FDA-approved drugs with Phase 3 trial programs involving tens of thousands of patients. They belong at the top of any evidence hierarchy for peptide-based weight management, and the distance between them and the next tier is substantial.

Dual gut-brain mechanism: GLP-1 receptor agonists work through two anatomically distinct pathways that reinforce each other:

Peripheral (gut) pathway: GLP-1 receptors on vagal afferent neurons in the gut wall detect meal arrival. Slowed gastric emptying (pyloric sphincter relaxation delay) extends the satiety signal duration. The vagal afferent signal travels to the nucleus tractus solitarius (NTS) in the brainstem, which integrates satiety information and suppresses appetite drive through downstream circuits.

Central (brain) pathway: GLP-1 receptors are also expressed in the hypothalamic arcuate nucleus (regulating homeostatic hunger), the area postrema (circumventricular organ with blood access), the mesolimbic system (hedonic eating circuits, reward), and the brainstem. Central GLP-1R activation suppresses both homeostatic hunger (the “I need fuel” signal) and hedonic eating drive (the “that looks rewarding” signal) simultaneously.

Why this produces “food noise” reduction: The mesolimbic GLP-1R activity — specifically in the ventral tegmental area (VTA) and nucleus accumbens — attenuates dopamine release in response to food cues. The hyperactivated reward signal that drives overconsumption in many people with obesity is dampened. This produces the “food noise” reduction that many patients describe as the most transformative aspect of GLP-1 therapy: the constant background preoccupation with food simply quiets. This is pharmacologically distinct from “willpower” — it represents attenuation of a neurobiological driver of overconsumption.

Semaglutide (Wegovy/Ozempic):

STEP 1 trial: ~15% mean body weight loss at 68 weeks vs. ~2.5% placebo (Wilding et al., PMID:33567185)
SELECT cardiovascular outcomes trial: 20% reduction in MACE in overweight/obese adults with established CVD, without diabetes (Lincoff et al., PMID:37952131) — the only weight management drug with cardiovascular mortality data at this scale
FLOW trial: 24% reduction in CKD composite outcome — new indication for CKD in type 2 diabetes (Perkovic et al., PMID:38587991)
FDA-approved indications: type 2 diabetes (Ozempic), obesity/overweight with comorbidity (Wegovy), CKD in type 2 diabetes (Ozempic, 2024)

Tirzepatide (Mounjaro/Zepbound):

Dual GLP-1 + GIP receptor agonist; GIP co-agonism produces additional weight loss effects beyond GLP-1 alone
SURMOUNT-1: ~22.5% weight loss at highest dose (15 mg) (Jastreboff et al., PMID:35658024)
SURMOUNT-5 (2025): First head-to-head randomized comparison vs. semaglutide 2.4 mg at 72 weeks: tirzepatide 10–15 mg produced ~20.2% weight loss vs. ~13.7% for semaglutide — the largest direct comparison in obesity pharmacotherapy history, confirming tirzepatide’s weight loss advantage (Wadden et al., PMID:39973393)
Additional FDA approvals: obstructive sleep apnea in obesity (2024); HFpEF (heart failure with preserved ejection fraction) in obesity pending

Why tirzepatide produces more weight loss: GIP receptor co-agonism adds several mechanisms beyond GLP-1 alone. GIP receptors are expressed in adipose tissue (regulating fat storage/release), hippocampus and amygdala (hedonic eating circuits), and pancreatic beta cells. GIP co-agonism shifts food reward circuits through limbic GIPR populations that are anatomically and functionally distinct from the VTA/NAc GLP-1R pathway. GIPR is expressed on hippocampal CA1/CA3 pyramidal neurons and basolateral amygdala (BLA) principal neurons — neither population expresses significant GLP-1R under physiological conditions. In hippocampal CA1/CA3 neurons, tirzepatide → GIPR/Gαs/adenylyl cyclase → cAMP/PKA → CREB Ser133 phosphorylation → BDNF transcription → TrkB/ERK → AMPA receptor GluA1 Ser831 phosphorylation → strengthened hippocampal long-term potentiation. The double-edged pharmacological consequence is that while this enhances hippocampal plasticity generally, sustained GIPR activation remodels the encoding strength of contextual food-associated memories — episodic memories linking specific environments, emotional states, or times of day to palatable food reward. Weakening the hippocampal contextual food memory trace reduces anticipatory eating (eating triggered by food-associated cues and contexts before homeostatic hunger develops) — a distinct feeding behavior from meal-triggered hunger. In BLA neurons, GIPR/Gαs/cAMP/PKA reduces excitability of BLA principal cells that encode negative emotional valence and stress-conditioned food associations; the BLA projects to the nucleus accumbens core (driving stress-induced incentive salience to high-calorie food) and to the prefrontal cortex (where BLA hyperactivation under stress degrades top-down inhibitory control of eating behavior). Attenuation of BLA excitability via GIPR/cAMP/PKA is mechanistically distinct from GLP-1R’s VTA/NAc reward suppression: GLP-1 reduces the salience of food cues (less “wanting” per cue event); GIP reduces the emotional triggering of eating by stress and context (less BLA-to-NAc incentive amplification under distress). These two mechanisms operate on different time scales — GLP-1’s VTA/GABAergic interneuron → phasic dopamine attenuation is meal-event-coupled, while GIP’s BLA/hippocampal plasticity effects accumulate over weeks of receptor occupancy, potentially explaining the progressive improvement in “emotional eating” control that some patients report with tirzepatide over months of treatment. It may also have a lean mass-preserving effect that GLP-1 monotherapy lacks, through a mechanism now being characterized in skeletal muscle. GIPR is expressed on skeletal myocytes, where GIPR/Gs activation → adenylyl cyclase → cAMP → PKA → phosphorylation of CREB at Ser133 → CREB-driven transcription of PGC-1α (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis and fatty acid oxidation. Elevated PGC-1α in muscle improves lipid oxidation capacity and reduces the reliance on muscle protein catabolism for gluconeogenic substrate during caloric deficit. Preclinical studies additionally show GIPR/cAMP/PKA activating Akt in myocytes through a PKA→PDK1 transactivation pathway independent of insulin signaling — Akt-mTORC1 signaling promotes myofibrillar protein synthesis that can partially counteract the mTORC1 suppression that drives lean mass catabolism under caloric restriction. This would provide tirzepatide with a muscle-preserving signal that semaglutide (GLP-1 monotherapy without GIP co-agonism) does not have. Whether this mechanism translates to clinically meaningful lean mass preservation in tirzepatide-treated patients is under active investigation; body composition data from SURMOUNT trials and the head-to-head SURMOUNT-5 will inform whether the lean mass advantage is real at clinical doses.

The critical limitation — weight regain on discontinuation: SURMOUNT-4 data showed participants regained approximately 14 percentage points of weight within 88 weeks of stopping tirzepatide (Aronne et al., PMID:38935394). This is not a drug failure — it reflects the chronic, relapsing biology of obesity. The molecular mechanism of regain makes the kinetics predictable: tirzepatide’s elimination half-life is approximately 5 days, so receptor occupancy at arcuate nucleus neurons falls to near-zero within 3–4 weeks of the last dose. As GLP-1R occupancy at arcuate POMC neurons dissipates, the pharmacologically-sustained α-MSH → MC4R/Gs/cAMP/PKA satiety tone declines toward baseline. Simultaneously, the GLP-1R-mediated suppression of NPY/AgRP co-expression in the adjacent orexigenic neuron population is removed: AgRP re-engages as an endogenous MC4R inverse agonist (it actively reverses MC4R/Gs signaling rather than merely competing with α-MSH), restoring the full hypothalamic orexigenic drive that was pharmacologically blunted during treatment. In the mesolimbic circuit, VTA GLP-1R occupancy that was attenuating phasic dopamine release to food-cue stimuli disappears — dopamine transient amplitudes at NAc shell return toward pre-treatment levels, restoring the hedonic salience (“wanting”) of calorie-dense foods. If the underlying diet-induced leptin resistance that characterized the pre-treatment state has not been resolved (adipocytes retain excess lipid stores for weeks after cessation as body weight rises), LepRb/JAK2/STAT3 signaling at AgRP neurons remains blunted by SOCS3-mediated receptor desensitization — the hypothalamic defended weight set point therefore re-engages at the elevated body weight the system was defending before treatment began, not at the pharmacologically-reduced treatment endpoint weight. The net result is simultaneous increased appetite (AgRP/NPY reactivation), increased food reward salience (VTA dopamine restoration), and a re-established energy homeostasis signaling system that drives caloric intake upward until adipose mass and circulating leptin/adiponectin tone reach the pre-treatment defended equilibrium — explaining why the regain is predominantly fat mass, follows an exponential-then-plateau trajectory, and converges on approximately the pre-treatment weight rather than stopping at a new lower set point. These medications must be continued long-term to maintain their effects.

Insurance and access:

With commercial insurance for diabetes: typically covered with moderate copay ($25–100/month)
With commercial insurance for obesity alone: highly variable; some plans cover, many don’t; improving with 2025 coverage mandates
Medicare: Wegovy covered for obesity since 2024 CMMI pilot; coverage expanding
Without insurance: $900–$1,400/month branded; compounded versions where legally available $100–300/month
Prior authorization is common — requires documentation of BMI threshold, comorbidities, and often a covered first-line trial

Tesamorelin (Egrifta) — Visceral Fat Reduction

Tesamorelin is a GHRH analogue with FDA approval for HIV-associated lipodystrophy — visceral fat accumulation driven by antiretroviral therapy. It is the only non-GLP-1 peptide with FDA approval for a fat-reduction indication.

How it works: By stimulating pulsatile GH secretion, tesamorelin raises IGF-1, which promotes lipolysis — particularly in visceral adipose tissue, which has higher GH receptor density than subcutaneous fat. This creates preferential visceral fat reduction, which is also the most metabolically harmful fat depot.

The molecular mechanism by which GH drives adipocyte lipolysis — and why visceral fat is preferentially affected — is worth understanding because it explains both the clinical specificity and the metabolic side effect profile. GH binds the growth hormone receptor (GHR), a preformed homodimer on adipocyte membranes that uses the same JAK2/STAT5b signaling pathway described for tenocytes and other GH-responsive cells. However, in adipocytes, the critical STAT5b-driven transcriptional outputs are different from muscle and bone: STAT5b binds GAS elements in the promoters of LIPE (hormone-sensitive lipase, HSL) and PNPLA2 (adipose triglyceride lipase, ATGL) — the two key lipases in the adipocyte lipolysis cascade. This is a genomic effect (hours-scale transcription and protein synthesis) distinct from the acute PKA-driven HSL phosphorylation that β3-AR agonism produces; STAT5b-driven HSL and ATGL transcription increases the total amount of lipolytic enzyme protein rather than activating existing enzyme, shifting the adipocyte’s resting lipolytic capacity upward over days to weeks of sustained GH treatment. With more ATGL and HSL protein per cell, the sequential triglyceride hydrolysis cascade (ATGL → DG → HSL → MG → MGL → glycerol + 3 free fatty acids) operates at a higher baseline rate, independent of sympathetic tone or insulin status.

Simultaneously, GH/JAK2 serine-phosphorylates IRS-1 (at Ser307 and Ser636/639) in adipocytes — the same insulin-desensitizing mechanism described for liver and muscle. In adipocytes specifically, insulin’s primary anabolic action is stimulating fatty acid synthase (FAS) and activating acetyl-CoA carboxylase (ACC) via PI3K/Akt → reduced de novo lipogenesis. GH-induced IRS-1 serine phosphorylation blocks this insulin-lipogenic signal → de novo fat synthesis falls while STAT5b-driven lipolysis capacity rises → net adipocyte triglyceride content decreases. This is mechanistically why tesamorelin causes fat loss rather than weight gain despite elevating IGF-1 (an anabolic hormone): in adipose tissue, the dominant GH effect is genomic upregulation of lipolytic enzymes and suppression of insulin-stimulated lipogenesis; the anabolic IGF-1 effects predominate in muscle and bone where the cellular machinery is oriented toward protein and matrix synthesis.

Why visceral fat is disproportionately reduced: Visceral adipose tissue (VAT, particularly omental and mesenteric depots) expresses 2–3× higher GHR mRNA and protein density than subcutaneous adipose tissue in humans. More surface GHR per cell → more JAK2/STAT5b transactivation per GH pulse → proportionally greater HSL and ATGL transcription → higher lipolytic capacity per cell than subcutaneous adipocytes receiving the same GH pulse. This receptor density difference is the molecular explanation for the preferential visceral fat loss observed in tesamorelin trials. A second metabolic consequence compounds the benefit: VAT is drained by the portal vein directly to the liver, meaning VAT-derived free fatty acids reach the liver at concentrations proportional to VAT mass. Reduced VAT from tesamorelin → lower portal FFA flux → reduced hepatic PKCε activation (DAG-driven PKCε inhibits insulin receptor tyrosine kinase activity in hepatocytes) → improved hepatic insulin sensitivity → reduced fasting glucose and hepatic fat accumulation. This portal FFA → hepatic insulin sensitivity pathway explains why tesamorelin’s visceral fat reduction produces metabolic improvements (HOMA-IR, triglycerides, lipid profile) that exceed what simple caloric deficit of equivalent fat mass would predict.

What the evidence shows:

In the approved indication (HIV lipodystrophy): consistent, significant reduction in visceral fat (~15–20% by trunk fat area) at 26 weeks
The LIPO-010 trial is investigating tesamorelin specifically for lean-mass preservation during GLP-1 therapy — a rational combination given complementary mechanisms: GLP-1 reduces total weight; tesamorelin preferentially targets visceral fat and preserves lean mass through the anabolic IGF-1 signal
Off-label use in metabolically healthy adults without HIV lipodystrophy has less defined evidence; the insulin resistance effect of GH elevation may offset visceral fat benefits in pre-diabetic patients

Critical monitoring: Glucose and IGF-1 must be monitored. GH has counter-regulatory effects on insulin (can worsen insulin resistance). Contraindicated in active malignancy.

Access: Prescription; available through 503A/503B compounding pharmacies as a GHRH analogue. Full guide: Tesamorelin: The GHRH Analogue Guide.

Tier 2: Completed Phase 2–3 Trials — Limited or Inconclusive Evidence

AOD-9604 (Fragment 176-191)

AOD-9604 is the most extensively clinically studied weight-focused peptide outside the GLP-1 class. It is a fragment of the C-terminus of human growth hormone (amino acids 176–191), engineered to retain lipolytic properties while eliminating GH’s anabolic effects.

The engineering rationale: Full-length GH acts on GH receptors to stimulate both anabolic effects (IGF-1 production, protein synthesis, bone growth) and lipolytic effects (fat mobilization). These effects are mediated by different receptor binding domains. AOD-9604 isolated the lipolytic domain — the theory being that you could have the fat-burning effects without the insulin resistance, IGF-1 elevation, and malignancy risk of full GH.

Mechanism: AOD-9604 acts through β3-adrenergic receptors on adipocytes — the same receptor that regulates thermogenesis in brown adipose tissue and lipolysis in white adipose tissue. This is distinct from the GLP-1/appetite pathway entirely. β3-AR activation increases intracellular cAMP, which activates PKA — and the full lipolytic cascade that follows is more precisely understood than the simple “HSL activates” shorthand suggests. The lipid droplet surface is coated by perilipin-1, a phosphoprotein that normally acts as a physical barrier protecting stored triglycerides from lipase access. PKA phosphorylates perilipin-1 at multiple Ser residues (including Ser492 and Ser517); this phosphorylation triggers a conformational change that releases ABHD5/CGI-58, a co-activator protein bound to perilipin-1 in the basal state → free ABHD5 binds and activates ATGL (adipose triglyceride lipase) on the lipid droplet surface → ATGL catalyzes the first and rate-limiting hydrolysis step, cleaving one fatty acid from triglycerides to produce diglycerides (DG) and one free fatty acid. PKA simultaneously phosphorylates HSL (hormone-sensitive lipase) at Ser660 and Ser563 → phospho-HSL translocates from the cytosol to the perilipin-1-coated droplet surface and is now also accessible → HSL cleaves DG to monoglycerides (MG) and a second free fatty acid → monoglyceride lipase (MGL) completes the final hydrolysis, releasing the third fatty acid and glycerol. The sequential ATGL → HSL → MGL cascade is why effective lipolysis requires all three enzymes: ATGL generates substrate for HSL, and HSL generates substrate for MGL. The net output — three free fatty acids plus one glycerol per triglyceride molecule — is released into circulation for uptake by skeletal muscle and liver for β-oxidation. This mechanistic precision also explains AOD-9604’s selectivity: because it acts via β3-AR/cAMP/PKA/perilipin-1/ATGL rather than the GH receptor’s JAK2/STAT5/IGF-1 axis, it does not trigger IGF-1 elevation or systemic insulin resistance. AOD-9604 also inhibits lipogenesis (new fat synthesis) and stimulates fatty acid oxidation, and both effects operate through the same cAMP/PKA signal that drives lipolysis — targeting a different enzymatic node downstream.

Lipogenesis suppression and β-oxidation activation via ACC phosphorylation: PKA phosphorylates acetyl-CoA carboxylase (ACC) at Ser79, an inhibitory site — the same site that AMPK phosphorylates under energy deficit. Phospho-ACC at Ser79 is catalytically inactive: it cannot carboxylate acetyl-CoA to produce malonyl-CoA. Malonyl-CoA is simultaneously (1) the essential two-carbon chain-extension donor for fatty acid synthase (FAS) during de novo lipogenesis, and (2) the primary allosteric inhibitor of CPT1 (carnitine palmitoyltransferase 1) — the outer mitochondrial membrane enzyme that rate-limits long-chain fatty acid entry into the mitochondrial matrix by conjugating them to carnitine. When PKA phosphorylates ACC → malonyl-CoA falls → two simultaneous and mechanistically linked consequences follow: (1) de novo lipogenesis falls because FAS loses its chain-elongation substrate → fewer new triglycerides are assembled from acetyl-CoA derived from excess carbohydrate or protein; (2) CPT1 is disinhibited because its allosteric inhibitor has been removed → long-chain acyl-CoAs (released by the ATGL/HSL lipolytic cascade) can be conjugated to carnitine by CPT1 → cross into the mitochondrial matrix → enter β-oxidation → acetyl-CoA → TCA cycle → ATP. The ACC/malonyl-CoA switch is self-reinforcing: lipolysis generates free fatty acids, some of which are immediately conjugated to carnitine by the disinhibited CPT1 and oxidized in the same mitochondria, preventing fatty acid re-esterification back into storage triglycerides. This integration of perilipin-1 (initiation), HSL (DG and MG hydrolysis), and ACC (lipogenesis suppression + β-oxidation enablement) explains why AOD-9604 shifts net adipocyte lipid balance toward depletion across multiple enzymatic nodes simultaneously — and why β3-AR agonism produces a more comprehensive anti-lipogenic effect than simply releasing fatty acids into circulation (Heffernan et al., PMID:11713213).

What the evidence shows:

Phase 2 trials in Australia: statistically significant body weight reduction vs. placebo, particularly in participants with higher baseline BMI
Phase 3 trials: results were less consistent than Phase 2; Metabolic Pharmaceuticals did not pursue FDA drug approval
2014 FDA GRAS (Generally Recognized As Safe) determination: AOD-9604 as a food ingredient — an unusual regulatory pathway that validated safety at specified doses but is not drug approval and does not establish efficacy
No IGF-1 stimulation, no glucose intolerance — the safety advantage over full GH is confirmed

The honest assessment: AOD-9604 completed the most extensive clinical testing of any research peptide in the weight space — and Phase 2 success followed by Phase 3 disappointment is the most common outcome in drug development. The compound is not a failed drug; it is a compound that didn’t meet the Phase 3 bar. That bar is high, and the effects may be real but modest relative to the commercial viability threshold.

Several mechanistic factors explain why β3-AR agonism tends to produce real-but-modest effects that attenuate under sustained conditions. Receptor desensitization: continuous β3-AR occupancy triggers GRK2/3 (G protein-coupled receptor kinase) phosphorylation of the receptor’s intracellular C-terminus → β-arrestin-2 recruitment → clathrin-coated pit internalization → reduced β3-AR surface density. Unlike β1/β2-ARs which rapidly recycle, β3-AR has a longer resensitization cycle; chronic agonist exposure in the context of a multi-week or multi-month trial progressively reduces surface receptor availability in adipocytes, meaning the lipolytic signal through HSL/ATGL weakens even as agonist concentration is maintained. Thermogenic adaptation: β3-AR/cAMP/PKA/CREB-driven UCP1 expression in BAT and beiged WAT increases initially, but as β3-AR surface density declines, the downstream p38 MAPK/ATF2 → PRDM16/PGC-1α → UCP1 transcriptional output plateaus — UCP1 protein may remain elevated from initial induction, but less of it is activated per thermogenic stimulus because β3-AR/Gs coupling efficiency has declined, reducing cAMP amplitude per agonist-receptor interaction. Compensatory appetite upregulation: reduced energy expenditure from thermogenesis signals through VMH AMPK, which detects lower substrate flux and disinhibits NPY/AgRP arcuate circuits → increased hunger and caloric intake that partially offsets the caloric expenditure gain. This AMPK-mediated counterregulation is independent of GLP-1R food noise suppression (which β3-AR agonism does not address), so compensation is relatively unconstrained. Phase 3 population heterogeneity: Phase 2 trials enrolled motivated participants who often had above-average BAT depot volume and higher β3-AR expression density in omental fat; larger Phase 3 populations include individuals with lower β3-AR density, minimal recruitable BAT, and higher metabolic compensation capacity — all of which dilute the mean effect size below the primary endpoint threshold, even when a subset of participants achieve meaningful responses.

Access: Not on FDA’s approved bulk substance list for compounding. Available through gray-market research peptide vendors without pharmaceutical quality assurance.

Tier 3: GH Secretagogues — Body Composition, Not Weight Loss

GH secretagogues — ipamorelin, CJC-1295, sermorelin — are frequently mentioned in weight loss discussions, but this framing is importantly misleading.

What they do:

Stimulate pulsatile GH release → raise IGF-1
Shift body composition: reduce fat mass (particularly visceral), increase lean mass — through three distinct molecular mechanisms. For fat reduction: GH directly activates adipocyte HSL (hormone-sensitive lipase) and ATGL (adipose triglyceride lipase) through JAK2/IRS-1/PI3K/Akt signaling in adipocytes (an insulin-like proximal cascade, paradoxically, that acts in a transient lipolytic rather than lipogenic context). GH also suppresses LPL (lipoprotein lipase) transcription in adipocytes via STAT5b through a dual mechanism: (1) phospho-STAT5b homodimers bind a negative GAS element in the LPL proximal promoter and recruit HDAC3/NCoR corepressor complexes → histone deacetylation at the LPL promoter → reduced LPL mRNA transcription; (2) STAT5b simultaneously drives transcription of ANGPTL4 (angiopoietin-like protein 4) in adipocytes → secreted ANGPTL4 binds the catalytic lid of LPL at the heparan sulfate proteoglycan attachment site on the capillary endothelial surface → LPL is displaced from its endothelial anchoring site and inactivated extracellularly → VLDL-triglyceride hydrolysis at the adipose capillary surface is blocked → circulating VLDL-derived fatty acids cannot be liberated and taken up for adipocyte re-esterification; these two arms — reduced LPL protein synthesis and extracellular LPL inactivation via ANGPTL4 — converge to reduce triglyceride uptake from circulating VLDL into fat cells. Visceral adipocytes express substantially higher GH receptor (GHR) density than subcutaneous adipocytes — approximately 2–3 fold more GHR per cell in the omental/mesenteric depots — meaning the same circulating GH pulse produces disproportionately greater HSL/ATGL activation in visceral fat. Elevated free fatty acids released by visceral lipolysis enter portal circulation, are processed by the liver, and do not re-deposit in central fat when GH tone is maintained. For lean mass: IGF-1 (produced hepatically in response to GH/GHR/JAK2/STAT5b → IGF-1 gene transcription) signals through IGF-1R on skeletal myocytes → IRS-1/PI3K/PIP₃/PDK1/Akt Thr308 → fully active Akt → mTORC1 (via TSC1/TSC2/Rheb inhibition) → S6K1 and 4E-BP1 → accelerated cap-dependent mRNA translation of myosin heavy chain and actin → net positive muscle protein balance. IGF-1 simultaneously suppresses MAFbx/Atrogin-1 and MuRF1 (the E3 ubiquitin ligases responsible for proteolytic muscle protein breakdown) via Akt → FOXO1/FOXO3a Ser256/Thr32 phosphorylation → 14-3-3 cytoplasmic sequestration → reduced atrogene transcription.
Net effect on scale weight: often minimal or modestly negative — composition improves more than the scale moves

What they do NOT do — and why, mechanistically:

Not comparable to GLP-1 agonists for weight loss magnitude — because GH secretagogues reduce fat and add lean mass without creating a meaningful sustained caloric deficit. Patients on ipamorelin or CJC-1295 may lose 1–3 kg of fat over months while gaining lean mass; GLP-1 agonists create pharmacologically-enforced caloric deficits producing 15–22% total weight reduction. These are different magnitudes of intervention for different biological problems.
Do not suppress appetite meaningfully — GH secretagogues act on receptors (GHRH-R/Gs on pituitary somatotrophs for sermorelin/CJC-1295; GHSR-1a/Gq on pituitary for ipamorelin) that are not expressed on the hypothalamic neurons controlling appetite. The downstream GH pulse raises IGF-1, but neither GH nor IGF-1 at physiological concentrations activates GLP-1R on arcuate POMC neurons or modulates NPY/AgRP orexigenic tone. Crucially, GH secretagogues have no mechanism to attenuate VTA dopamine neuron firing or NAc cue-reactivity — the mesolimbic reward circuit that drives hedonic eating in obesity is entirely unaddressed. Since GH and IGF-1 do not cross the blood-brain barrier efficiently at circulating concentrations produced by secretagogue therapy, central appetite circuits are pharmacologically untouched.
Do not address insulin resistance — and may worsen it: GH’s counter-regulatory effect on insulin operates through a specific post-receptor mechanism. GH → GHR/JAK2 → JAK2 serine-phosphorylates IRS-1 at Ser307 and Ser636/639 in hepatocytes and skeletal muscle (the same JAK2/IRS-1 interaction that drives lipolysis in adipocytes, but IRS-1 serine phosphorylation in insulin target tissues has an inhibitory rather than lipolytic consequence). Phospho-IRS-1 Ser307 cannot recruit the PI3K p85 regulatory subunit → reduced PIP₃ production → attenuated Akt Thr308 phosphorylation → impaired GLUT4 vesicle translocation in skeletal muscle and reduced glycogen synthase activation in liver. This GH-induced hepatic and muscle insulin resistance is the mechanism behind glucose intolerance monitoring requirements for secretagogue users. In a patient who already has obesity-driven insulin resistance (driven by DAG/ceramide IRS-1 Ser307 phosphorylation from elevated circulating free fatty acids), adding GH-driven JAK2/IRS-1 Ser307 phosphorylation amplifies the same bottleneck rather than addressing the root cause. The contrast with GLP-1 agonists is exact: GLP-1R/cAMP/PKA → IKKβ inhibition → NF-κB/SOCS3 suppression → restored LepRb/JAK2/STAT3 → reduced hypothalamic inflammation → improved leptin sensitivity and insulin signal transduction. GH secretagogues deepen the insulin-signaling impairment; GLP-1 agonists reverse it.

The appropriate framing is body composition optimization, not weight loss. For a man with somatopause-related visceral fat accumulation and declining lean mass, GH secretagogues address a different biological problem than obesity. Conflating the two creates unrealistic expectations and can lead patients away from evidence-based obesity treatment.

Mandatory monitoring: IGF-1 must stay within age-appropriate ranges. Elevated IGF-1 is associated with increased cancer risk (Renehan et al., PMID:15110491). Glucose monitoring required.

Access: Prescription required; available through compounding pharmacies. Full guides: Ipamorelin and CJC-1295 · Sermorelin.

Tier 4: Theoretical or Indirect Relevance — Limited Weight Evidence

MOTS-c: The Exercise Mimetic

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a peptide encoded in mitochondrial DNA — an unusual location for a peptide hormone, as almost all proteins are encoded by nuclear DNA. It acts as an “exercise mimetic” because its release is triggered by metabolic stress and physical activity, and it activates pathways that overlap with exercise’s metabolic effects.

The biology: Under metabolic stress or exercise, MOTS-c is transcribed in mitochondria and can translocate to the nucleus — a phenomenon called retrograde mitochondrial-nuclear signaling. In the nucleus, it activates AMPK (AMP-activated protein kinase) and SIRT1, which together improve insulin sensitivity, increase fat oxidation, and shift fuel preference toward lipid metabolism. SIRT1 (Sirtuin-1) is a NAD⁺-dependent protein deacetylase whose insulin-sensitizing actions are mechanistically distinct from — and complementary to — the AMPK/ACC/CPT1 fat-oxidation axis: (1) PGC-1α deacetylation — SIRT1 removes acetyl groups from PGC-1α at Lys183, Lys253, and Lys450 → full transcriptional coactivator activity → nuclear respiratory factor (NRF1/NRF2)/TFAM induction → mitochondrial DNA replication and electron transport chain subunit transcription → expanded oxidative capacity → reduced accumulation of lipotoxic intermediates (diacylglycerol, ceramide) that activate PKCε/PKCθ → attenuated PKC-mediated IRS-1 Ser307 phosphorylation (the primary serine event that uncouples insulin receptor activation from downstream PI3K engagement); (2) FOXO1 deacetylation — SIRT1 deacetylates FOXO1 at Lys242/Lys245/Lys262 → FOXO1 cytoplasmic sequestration → suppressed PTP1B gene transcription (PTP1B is the tyrosine phosphatase that dephosphorylates Akt at Thr308, directly reversing insulin signaling) → sustained Akt/AS160 phosphorylation → GLUT4 vesicle translocation to plasma membrane; (3) NF-κB p65 deacetylation at Lys310 → attenuated transcription of TNF-α and IL-6 → reduced IKKβ activation → less IRS-1 Ser307 phosphorylation from the inflammatory arm. These three substrates — PGC-1α (lipotoxicity arm), FOXO1 (phosphatase arm), NF-κB p65 (inflammatory arm) — act in parallel, meaning SIRT1 addresses branches of insulin resistance that AMPK’s malonyl-CoA/CPT1 axis does not directly reach. MOTS-c also appears to reduce mitochondrial reactive oxygen species and increase mitochondrial biogenesis. The AMPK activation mechanism is worth understanding because it explains precisely how MOTS-c shifts fuel toward fat: MOTS-c inhibits steps in the folate cycle and de novo purine biosynthesis within the cell — this causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to accumulate. AICAR is an endogenous activator of AMPK, essentially mimicking a low-energy (high AMP:ATP ratio) state. Activated AMPK then phosphorylates and inactivates ACC (acetyl-CoA carboxylase) — the enzyme that produces malonyl-CoA. Malonyl-CoA is the cell’s “fat synthesis in progress” signal that simultaneously inhibits CPT1 (carnitine palmitoyltransferase 1), the gatekeeper enzyme that shuttles long-chain fatty acids into the mitochondrial matrix for β-oxidation. With ACC inactivated: malonyl-CoA falls → CPT1 is disinhibited → fatty acids enter mitochondria → β-oxidation produces acetyl-CoA → Krebs cycle → ATP. The same AICAR/AMPK/ACC/CPT1 pathway is activated by exercise — MOTS-c is released during physical activity and may mechanistically explain part of exercise’s fat-oxidation shift at the molecular level.

What the animal data shows: In obese mice on high-fat diets, MOTS-c injection reversed obesity and insulin resistance, restoring normal metabolic parameters. In aged mice, MOTS-c improved exercise capacity and reversed sarcopenia features. The effect size in animal models is striking.

What human evidence shows: Essentially none in the context of weight loss. A Phase 1 trial is underway (Cohbar CB5945 analog, referenced in the pipeline guide), but no efficacy data exists. Do not confuse compelling mouse data with established human therapy.

The translation gap is mechanistically specific, not just a matter of awaiting confirmation. Endogenous MOTS-c is released in response to specific intracellular metabolic stress — ROS elevation, membrane potential disruption, high-intensity energetic workload — and its downstream AMPK activation is coupled to that cellular context. The AICAR accumulation mechanism (inhibition of folate cycle enzymes SHMT/MTHFR and purine biosynthesis intermediates at ATIC/ADSL → intracellular AICAR buildup → AMPK Thr172 phosphorylation via LKB1) requires sustained intracellular MOTS-c concentrations alongside an elevated AMP:ATP ratio: LKB1 activation is primarily driven by intracellular energy status rather than cell-surface receptor occupancy, meaning exogenous MOTS-c arriving through systemic circulation encounters adipocytes and myocytes that are not in the energy-depleted state that makes the downstream cascade proceed. When MOTS-c arrives via subcutaneous injection in a resting human, the metabolic context (depleted ATP, elevated AMP, oxidative stress) that gates AMPK activation downstream of MOTS-c is absent — removing one of the two required inputs to LKB1/AMPK engagement. Pharmacokinetics impose a second barrier: MOTS-c is a 16-amino-acid peptide (~2 kDa) subject to plasma protease degradation and renal filtration; tissue distribution to relevant metabolic depots (visceral adipose, skeletal muscle) from subcutaneous injection in a large-mass organism reduces delivered intracellular concentration well below the levels achieved in the mouse intraperitoneal dosing models, where peritoneal absorption delivers peptide directly to splanchnic circulation and visceral tissue beds at concentrations that dwarf what subcutaneous pharmacokinetics can sustain. The rodent obesity studies used supraphysiologic MOTS-c doses in metabolically stressed animals (high-fat diet, aged) — conditions that both maximized tissue drug exposure and ensured the intracellular metabolic context necessary for AMPK cascading was present. Translating this to a resting human without matched metabolic stress removes both conditions simultaneously.

GHK-Cu, BPC-157, TB-500

None of these have weight loss or fat reduction as a studied application. Marketing that positions them as weight-management compounds is not supported by the evidence base for any of them. GHK-Cu’s established applications are skin and wound healing; BPC-157 is GI protection and tissue healing; TB-500 is actin dynamics and wound healing.

Collagen Peptides

Collagen peptides support exercise recovery and joint health, which enables better training — which can improve body composition over time. Their role in weight management is as a protein source and connective tissue support during exercise, not as a metabolic or fat-loss agent. They are legitimate supplements with good safety profiles and legitimate, modest evidence for their actual indications.

The GLP-1 + Tesamorelin Combination

The most scientifically rational weight-management peptide combination being actively studied is GLP-1 agonist + tesamorelin:

GLP-1 agonist addresses total caloric intake, total weight, appetite pathways, and glucose homeostasis
Tesamorelin specifically targets visceral fat and helps preserve lean mass during GLP-1-induced weight loss through the anabolic IGF-1 signal
These are non-overlapping mechanisms addressing different aspects of body composition

The molecular basis for lean mass preservation specificity: The caloric deficit imposed by GLP-1-induced appetite suppression activates lean mass catabolism through two parallel mechanisms described earlier in this guide: (1) mTORC1 suppression from reduced insulin and dietary amino acid flux → reduced S6K1 and 4E-BP1 → falling myofibrillar protein synthesis rate; (2) cortisol/GR → FOXO1/FOXO3a → MuRF1 (TRIM63) and MAFbx/atrogin-1 (FBXO32) E3 ubiquitin ligase upregulation → ubiquitin-proteasomal degradation of myosin heavy chain and other contractile proteins. Tesamorelin’s IGF-1/Akt axis directly counteracts both mechanisms in skeletal muscle simultaneously: tesamorelin → GHR/JAK2/STAT5b → hepatic IGF-1 gene transcription → circulating IGF-1 → IGF-1R (IGF-1 receptor tyrosine kinase) on skeletal myocytes → IRS-1/PI3K/PIP₃/PDK1 → Akt Thr308 phosphorylation (full kinase activation). Active Akt then acts on both catabolism arms in parallel: (1) mTORC1 restoration: Akt phosphorylates TSC2 (tuberous sclerosis complex 2) at Thr1462 → TSC2 cannot GAP-inactivate Rheb-GTP → Rheb-GTP activates mTORC1 at the lysosomal membrane → S6K1/4E-BP1 phosphorylation → restored ribosome biogenesis and cap-dependent mRNA translation of myosin heavy chain and actin, directly counteracting the mTORC1 suppression from caloric restriction. (2) FOXO neutralization: Akt phosphorylates FOXO1 at Ser256 and FOXO3a at Thr32 → 14-3-3 proteins dock at the phosphorylated Ser/Thr sites → cytoplasmic sequestration of FOXO transcription factors → FOXO cannot translocate to the nucleus to access FREs in the MuRF1 and MAFbx promoters → atrogene expression falls → ubiquitin-proteasomal myosin heavy chain catabolism is suppressed. The tesamorelin/IGF-1/Akt mechanism thus acts as a point-counterpoint to GLP-1’s caloric restriction effect on muscle: GLP-1 creates the sustained caloric deficit (triggering both catabolism arms via mTOR suppression and cortisol/FOXO), while IGF-1 from tesamorelin selectively restores anabolic and anti-catabolic signaling in skeletal myocytes — without attenuating GLP-1’s central appetite suppression or peripheral glucose homeostasis effects. This mechanistic orthogonality is what makes the combination conceptually distinct from simply increasing protein intake, which addresses mTOR substrate availability but does not suppress FOXO-driven atrogene transcription.

The LIPO-010 trial design involves tirzepatide plus tesamorelin vs. tirzepatide alone, with DEXA-measured body composition (lean mass and fat mass separately) as primary endpoints. This is exactly the right trial design for the question: does tesamorelin prevent the lean mass loss that occurs with GLP-1 therapy? Results are not yet published.

For a broader framework on combining peptides, see Peptide Combination Therapy: Evidence and Principles.

What to Ignore

“Peptide fat burners”: This is marketing language, not a regulatory or scientific category. Ask specifically: what human clinical trial data supports this compound for fat loss at a meaningful magnitude?

High-dose exogenous GH: Can shift body composition, but at significant cost — insulin resistance, carpal tunnel syndrome, fluid retention, and with chronic use, potential malignancy risk. The 2007 Liu meta-analysis of GH for healthy adults established that body composition effects do not translate to functional benefits and come with substantial adverse effects (Liu et al., PMID:17227934). GH secretagogues exist to provide GH axis stimulation within physiological bounds.

Peptide stacks without rationale: Combinations of BPC-157 + TB-500 + ipamorelin + GHK-Cu marketed as “weight loss stacks” have no clinical basis. These are compounds from completely different mechanistic categories assembled to justify higher-cost protocols.

Oral peptide supplements: Most oral peptide products are degraded in the GI tract before absorption — aminopeptidases in the gut cleave peptide bonds within minutes. The exception is GLP-1 agonists specifically engineered for oral stability (Rybelsus uses a SNAC (sodium N-(8-(2-hydroxybenzoyl) aminocaprylate) absorption enhancer — the oral formulation is itself a significant pharmaceutical innovation). The SNAC mechanism: Rybelsus tablets contain an approximately 300:1 ratio of SNAC to semaglutide by mass. When the tablet dissolves in the stomach, SNAC reaches millimolar concentrations locally at the gastric mucosa — far exceeding what is achievable in the small intestine where most oral drug absorption occurs. SNAC’s amphipathic structure (a fatty acid chain coupled to a salicylic acid-derived head group) allows it to intercalate transiently into the phospholipid bilayer of gastric mucosal epithelial cells, increasing membrane fluidity and paracellular junctional permeability at that specific location. Simultaneously, SNAC is a weak acid that locally buffered the microenvironment to pH 5–6, which both reduces pepsin activity (pepsin is optimally active at pH 1.5–3.5 and loses activity above pH 4) and promotes the unionized form of SNAC that most efficiently partitions into cell membranes. The combination — local pepsin inactivation + transient mucosal permeability enhancement — creates a short absorption window (~30 minutes) during which semaglutide crosses the gastric epithelium before encountering the proteolytic environment of the small intestine. Bioavailability of oral semaglutide (Rybelsus) is approximately 0.4–1% — far below injectable forms (nearly 100%), which is why the oral dose is 3–14 mg versus the injectable weekly dose of 0.25–2.4 mg, and why it must be taken fasting with a small amount of water to prevent dilution of the critical SNAC concentration gradient at the stomach wall. This mechanism is entirely specific to the gastric SNAC microenvironment and cannot be replicated by generic protein/peptide oral supplements that lack a pharmaceutical-grade absorption enhancer system.). Generic “peptide supplements” promising weight loss through peptide mechanisms are implausible pharmacologically.

Decision Framework by Goal

Goal	Best-Evidenced Option	Evidence Level	Requires Rx
Significant weight loss (≥10%)	Semaglutide (Wegovy) or tirzepatide (Zepbound)	Strong — Phase 3 RCTs, 15–22% at 68 weeks	Yes
Visceral fat specifically	Tesamorelin (approved: HIV lipodystrophy)	Moderate — FDA-approved indication	Yes
Body composition (lean ↑ / fat ↓)	GH secretagogues off-label with monitoring	Moderate — body composition evidence, no long-term RCT	Yes
Lean mass preservation during GLP-1 therapy	GLP-1 + resistance exercise + protein target; GLP-1 + tesamorelin under study	Behavioral evidence strong; combination under trial	Yes (GLP-1); No (exercise/protein)
Exercise recovery support	Collagen peptides	Moderate — RCTs for joint and connective tissue	No
Fat metabolism research interest	AOD-9604	Phase 2/3 data, inconclusive, not FDA-approved	No (gray market only)
Metabolic aging/exercise mimetic interest	MOTS-c	Preclinical animal data only	No (gray market only)

Practical Starting Point

Consult a physician first. Obesity is a complex, chronic medical condition requiring a full clinical picture.
GLP-1 agonists are the evidence standard for weight loss. If you qualify (BMI ≥30, or ≥27 with a weight-related comorbidity), semaglutide or tirzepatide are the only peptide-class medications with robust evidence. They require a prescription and medical monitoring.
Build the metabolic foundation. Resistance exercise 2–3×/week, protein 1.2–1.6 g/kg/day, adequate sleep (GH is primarily released during sleep), and stress management are the non-negotiable behavioral components. GLP-1 agonists work best with lifestyle support.
If body composition rather than weight is the goal, GH secretagogue discussion with an endocrinologist makes sense if IGF-1 decline and somatopause are documented with baseline labs.
Approach gray-market compounds with explicit risk awareness. AOD-9604, MOTS-c, and similar research peptides come without pharmaceutical quality assurance, legal prescribing access, or established human safety profiles.

Citations

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. PMID:33567185
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-32. PMID:37952131
Perkovic V, et al. Effects of semaglutide on chronic kidney disease (FLOW). N Engl J Med. 2024;391:109-121. PMID:38587991
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. PMID:35658024
Wadden TA, et al. Tirzepatide versus semaglutide for obesity (SURMOUNT-5). N Engl J Med. 2025. PMID:39973393
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. PMID:38935394
Renehan AG, et al. IGF-I, IGF binding protein-3, and cancer risk: systematic review. Lancet. 2004;363:1346-53. PMID:15110491
Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142:5182-9. PMID:11713213
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab. 2015;21:443-54. PMID:25738459
Liu H, et al. Safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146:104-15. PMID:17227934

Peptides for Weight Loss: What the Evidence Actually Shows

Obesity as a Neurobiological Disease: Why This Changes the Framework

Adipose Tissue Biology: Why Different Peptides Target Different Fat Compartments

Visceral vs. Subcutaneous Fat

Brown Adipose Tissue (BAT) and Thermogenesis

The Lean Mass Loss Problem: Why Scale Weight Alone Is Misleading

Tier 1: FDA-Approved — Strong Clinical Evidence

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide): How They Actually Work

Tesamorelin (Egrifta) — Visceral Fat Reduction

Tier 2: Completed Phase 2–3 Trials — Limited or Inconclusive Evidence

AOD-9604 (Fragment 176-191)

Tier 3: GH Secretagogues — Body Composition, Not Weight Loss

Tier 4: Theoretical or Indirect Relevance — Limited Weight Evidence

MOTS-c: The Exercise Mimetic

GHK-Cu, BPC-157, TB-500

Collagen Peptides

The GLP-1 + Tesamorelin Combination

What to Ignore

Decision Framework by Goal

Practical Starting Point

Citations

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?

Obesity as a Neurobiological Disease: Why This Changes the Framework

Adipose Tissue Biology: Why Different Peptides Target Different Fat Compartments

Visceral vs. Subcutaneous Fat

Brown Adipose Tissue (BAT) and Thermogenesis

The Lean Mass Loss Problem: Why Scale Weight Alone Is Misleading

Tier 1: FDA-Approved — Strong Clinical Evidence

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide): How They Actually Work

Tier 1b: FDA-Approved for a Related Indication

Tesamorelin (Egrifta) — Visceral Fat Reduction

Tier 2: Completed Phase 2–3 Trials — Limited or Inconclusive Evidence

AOD-9604 (Fragment 176-191)

Tier 3: GH Secretagogues — Body Composition, Not Weight Loss

Tier 4: Theoretical or Indirect Relevance — Limited Weight Evidence

MOTS-c: The Exercise Mimetic

GHK-Cu, BPC-157, TB-500

Collagen Peptides

The GLP-1 + Tesamorelin Combination

What to Ignore

Decision Framework by Goal

Practical Starting Point

Citations

Related Reading

Stay Informed on Peptide Research

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?